Impact of the inflammatory reaction on intermediary metabolism and nutrition status

Nutrition

Volumn 18, Issue 11-12, 2002, Pages 949-952

  Guirao, Xavier ^a  

^a HOSPITAL DE FIGUERES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLYCEROL; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6; LEPTIN; PROSTAGLANDIN E2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TYROSINE;

ANOREXIA; CACHEXIA; CALORIC INTAKE; CANCER PATIENT; CYTOKINE RELEASE; EARLY DIAGNOSIS; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; HUMAN; HYPERMETABOLISM; IMMUNE RESPONSE; INFLAMMATION; LEAN BODY WEIGHT; LIPID METABOLISM; LIPOLYSIS; MALNUTRITION; METABOLISM; NONHUMAN; NUTRITIONAL SUPPORT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTAKE; PROTEIN METABOLISM; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 0036846406     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(02)00989-9     Document Type: Article

References (75)

1. Kopf M., Baumann H., Freer G., et al. Impaired immune and acute-phase responses in interleukin 6-deficient mice. Nature. 368:1994;339.
2. Molotkov A., Satoh M., Tohyama C. Tumor growth and food intake in interleukin-6 gene knock-out mice. Cancer Lett. 132:1998;187.
3. Cahlin C., Körner A., Axelsson H., et al. Experimental cancer cachexia the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Nl background and eicosanoid dependent cachexia . Cancer Res. 60:2000;5488.
4. Costa G. Cachexia, the metabolic component of neoplasic diseases. Cancer. 37:1977;2327.
5. De Wys W. Anorexia in cancer patients. Cancer Res. 37:1977;2354.
6. Tracey K.J., Wei H., Manogue K.R., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 167:1988;1211.
7. Moldawer L., Andersson C., Gelin J., Lundholm K.G. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol. 254:1988;G450.
8. Mulligan H.D., Mahony S.M., Ross J.A., Tisdale M.J. Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-alpha or interleukin-6. Cancer Lett. 65:1992;239.
9. Uehara A., Sekiya C., Tagasugi Y., Namiki M., Arimura A. Anorexia induced by IL-1 involvement of corticotropin -releasing factor . Am J Physiol. 257:1989;R613.
10. Langstein S.F., Doherty G.M., Fraker D.L., Buresh C.M., Norton J.A. The roles of gamma interferon and tumor necrosis factor alfa in an experimental rat model of cancer cachexia. Cancer Res. 51:1991;2302.
11. Stovroff M.C., Fraker D.L., Swedenborg A., Norton J.A. Cachectin/tumor necrosis factor a possible mediator of cancer cachexia . Cancer Res. 48:1988;4567.
12. Grunfeld C., Wilking H., Neese R., et al. Persistence of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res. 49:1989;2554.
13. Moldawer L.L., Sherry B.E., Marano M.A., et al. Anticachectin antibodies attenuate the carcass lipid depletion in mice lewis lung carcinoma. J Am Coll Surg. 34:1988;429.
14. Tracey K., Morgello S., Brett K., et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest. 86:1990;2014.
15. Negri D., Mezzanica D., Sacco S., et al. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 15:2001;1.
16. Meguid M.M., Muscaritoli M., Beverly L., et al. The early cancer anorexia paradigm changes in plasma free tryptophan and feeding indexes . JPEN. 1992;16.
17. Varma M., Torelli G., Meguid M., et al. Potential strategies for ameliorating early cancer anorexia. J Surg Res. 81:1999;69.
18. Blaha V., Yang Z., Meguid M., et al. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia in vivo microdialysis study . Acta Med (Hradec Kralove). 41:1998;3.
19. Laviano A., Gleason J., Meguid M., et al. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor -bearing rats. J Invest Med. 48:2000;40.
20. Laviano A., Meguid M., Yang Z., et al. Cracking the riddle of cancer anorexia. Nutrition. 12:1996;706.
21. Grunfeld C., Zhao C., Fuller J., et al. Endotoxin and cytokines induce expression of leptin, the ob gene product in hamsters. J Clin Invest. 97:1996;2152.
22. Faggioni R., Fantuzzi G., Fuller J., et al. IL-1 beta mediates leptin induction during inflammation. Am J Physiol. 274:1998;R204.
23. Mantovani G., Maccio A., Mura L., et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage at different sites. J Mol Med. 78:2000;554.
24. Brown D., Berkowitz D., Breslow M. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab. 86:2001;162.
25. Hershman M.J., Habib N.A., George C.D., Wood C.B. Effect of cachexia on lipid saturation of erythrocyte membranes. Curr Surg. 44:1987;292.
26. Briddon S., Beck S.A., Tisdale M.J. Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model. Cancer Lett. 57:1991;49.
27. Legaspi A., Jeevanandam M., Starnes H.J., Brennan M.F. Whole body lipid and energy metabolism in the cancer patient. Metabolism. 36:1987;958.
28. Groundwater P., Beck S.A., Barton C., et al. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer. 62:1990;816.
29. Axelrod L., Costa G. The contribution of fat loss to weight loss in cancer. Nutr Cancer. 2:1980;81.
30. Patton J.S., Shepard H.M., Wilking H., et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natal Acad Sci USA. 83:1986;8313.
31. Mahoney S.M., Beck S.A., Tisdale M.J. Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour. Br J Cancer. 57:1988;385.
32. Starnes H.F., Warren R.S., Jeevanandam M., et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 82:1988;1321.
33. Strassmann G., Fong M., Kenney J.S., Jacob C.O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 89:1992;1681.
34. Matthys P., Dijkmans R., Proost P., et al. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer. 49:1991;77.
35. Bossola M., Muscaritoli M., Bellantone R., et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest. 30:2000;1107.
36. Noguchi Y., Yoshikawa T., Matsumoto A., Svaninger G., Gelin J. Are cytokines possible mediators of cancer cachexia? Surg Today. 26:1996;467.
37. Socher S.H., Martinez D., Craig J.B., Kuhn J.G., Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst. 80:1988;595.
38. Okada S., Okusaka T., Ishii H., et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 28:1998;12.
39. Wenger F., Jacobi C., Zieren J., et al. Tumor size and lymph node status in pancreatic carcinoma-is there a correlation to the preoperative immune function. Langenbecks Arch Surg. 384:1999;473.
40. Ikemoto S., Sugimura K., Yoshida N., et al. TNF alpha, IL-1 beta and Il-6 production by peripheral blood monocytes in patients with renal cell carcinoma. Anticancer Res. 20:2000;317.
41. Beck S., Tisdale M. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res. 47:1987;5919.
42. Costelli P., Carbo N., Tessitore L., et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 92:1993;2783.
43. Kawamura I., Moldawer L.L., Keenan R.A., et al. Altered amino acid kinetics in rats with progressive tumor growth. Cancer Res. 42:1982;824.
44. Pain V., Randall D., Garlick P. Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. Cancer Res. 1984;1054.
45. Lundholm K., Bennergard K., Svaninger E.G., Emery P.W., Rennie M.J. Efflux of 3 methyl-histidine from the leg in cancer patients who experience weight loss. Cancer Res. 42:1982;4807.
46. Belizario J.E., Katz M., Raw C.I. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma protein from cancer with weight loss. Br J Cancer. 63:1991;705.
47. Starnes H.F., Warren R.S., Brennan M.F. Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy. J Clin Invest. 80:1987;1384.
48. Waterhouse C., Jeanpretre N., Keilson J. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res. 39:1979;1968.
49. Fong Y., Moldawer L.L., Marano M., et al. Cachectin/TNF or IL-1 induces cachexia with redistribution of body proteins. Am J Physiol. 256:1989;R659.
50. Flores E.A., Bistrian B.R., Pomposelli J.J., et al. Infusion of tumor necrosis factor cachectin promotes muscle catabolism in the rat. J Clin Invest. 83:1989;1614.
51. Goodman M.N. Interleukin-6 induces skeletal muscle protein breakdown in rats. P S E B M. 205:1994;183.
52. Brenner D.A., Buck M., Feitelberg S.P., Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest. 85:1990;248.
53. Fong Y., Moldawer L.L., Wei H., et al. Influence of tumor location on cytokine production and host metabolism. Surg Forum. 41:1990;451.
54. Aderka D, Fischer S, Levo Y, Cachectin/tumor-necrosis factor production by cancer patients. Lancet 1985:1190.
55. Ardizzoia A., Lissoni P., Brivio F., et al. Tumor necrosis factor in solid tumors increased blood levels in the metastatic disease . J Biol Regul Homeost Agents. 6:1992;103.
56. Todorov P., Cariuk P., McDevitt T., et al. Characterization of a cancer cachectic factor. Nature. 379:1996;739.
57. Llovera M., García-Martínez C., Urgell N., López-Soriano F.J., Argiles J.M. Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer. 61:1995;138.
58. García-Martinez C., Llovera M., Agell N., López-Soriano F., Argilés J. Ubiquitin gene expression in skeletal muscle is increased by tumor necrosis factor a. Biochem Biophys Res Commun. 201:1994;682.
59. Ebisui C., Tsujinaka T., Morimoto T., et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsin B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond). 89:1995;431.
60. Lorite M., Smith H., Arnold J., et al. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by proteolysis-inducing factor (PIF). Br J Cancer. 85:2001;297.
61. Bozzetti F., Pagnoni A., Del Vecchio M. Excessive caloric expenditure as a cause of malnutrition in patients with cancer. Surg Gynecol Obstet. 150:1980;229.
62. Dempsey D., Feurer I., Knox L., et al. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer. 53:1984;1265.
63. Falconer J.S., Fearon K.C.H., Plester C.E., Ross J.A., Carter D. Cytokines, the acute phase response and Resting Energy Expenditure in cachectic patients with pancreatic cancer. Ann Surg. 219:1994;325.
64. Arbeit J., Lees D., Corsey R., Brennan M. Resting energy expenditure in controls and cancer patients with localizes and diffuse disease. Ann Surg. 199:1984;292.
65. van den Brekel S., Schols A., Dentener M., et al. The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer. 76:1997;1630.
66. Hansell D., Davis J., Burns H. The relationship between resting energy expenditure and weight loss in benign and malignant disease. Ann Surg. 203:1986;240.
67. Lindmark L., Bennegard K., Eden E., et al. Resting energy expenditure in malnourished patients with and without cancer. Gastroenterology. 87:1984;402.
68. Bosaeus I., Daneryd P., Svanberg E., Lundholm K. Dietary intake and resting energy expenditures in relation to weight loss in unselected cancer patients. Int J Cancer. 93:2001;380.
69. Jatoi A., Daly B., Hughes V., Dallal G., Roubenoff R. The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer. Lung Cancer. 23:1999;153.
70. Wigmore S.J., Fearon K.C., Maingay J.P., Ross J.A. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci. 92:1997;215.
71. Van der Poll T., Romijin J.A., Endert E., et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 261:1991;E457.
72. Roubenoff R., Roubenoff R.A., Cannon J.G., et al. Rheumatoid cachexia cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation . J Clin Invest. 93:1994;2379.
73. Hardin T.C., Koeller J.M., Kuhn J.G., Roodman D., Von Hoff D.D. Nutritional parameters observed during 28 day infusion of recombinant human tumor necrosis factor alpha. JPEN. 17:1993;541.
74. Elborn J.S., Cordon S.M., Western P.J., Macdonald I.A., Shale D.J. Tumour necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis. Clin Sci (Colch). 85:1993;563.
75. Hart D., Wolf S., Herndon D., et al. Energy expenditure and caloric balance after burn increased feeding leads to fat rather than lean mass accretion . Ann Surg. 235:2002;152.